ZyVersa Therapeutics Inc

NEW
NAS:ZVSA (USA)  
$ 1.05 -0.0298 (-2.76%) 11:08 PM EST
At Loss
P/B:
0.17
Enterprise V:
$ -597.00K
Volume:
101.76K
Avg Vol (2M):
1.82M
Trade In:
Volume:
101.76K
At Loss
Avg Vol (2M):
1.82M

Business Description

Description
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
Name Current Vs Industry Vs History
Cash-To-Debt 13.67
Equity-to-Asset 0.36
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate 5.8
3-Year EPS without NRI Growth Rate -6.7
3-Year FCF Growth Rate -6.3

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 40.16
9-Day RSI 37.98
14-Day RSI 35.68
3-1 Month Momentum % -42.66
6-1 Month Momentum % -74.38
12-1 Month Momentum % -83.52

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.03
Quick Ratio 0.03
Cash Ratio 0.01

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -80.4
Shareholder Yield % 2.49
Name Current Vs Industry Vs History
ROE % -185.01
ROA % -92.33
ROIC % -43.66
3-Year ROIIC % -8.91
ROC (Joel Greenblatt) % -37605.47
ROCE % -77.03

GF Value Rank

Name Current Vs Industry Vs History
PB Ratio 0.17
EV-to-EBIT 0.06
EV-to-EBITDA 0.06
EV-to-FCF 0.07
Earnings Yield (Greenblatt) % 1666.67
FCF Yield % -360.27

Financials

ZVSA's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:ZVSA

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

ZyVersa Therapeutics Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -113.748
Beta -
3-Year Sharpe Ratio -
3-Year Sortino Ratio -
Volatility % 131.59
14-Day RSI 35.68
14-Day ATR ($) 0.127011
20-Day SMA ($) 1.09238
12-1 Month Momentum % -83.52
52-Week Range ($) 0.9801 - 25
Shares Outstanding (Mil) 2.34

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

ZyVersa Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

ZyVersa Therapeutics Inc Stock Events

Financials Calendars
Event Date Price ($)
No Event Data

ZyVersa Therapeutics Inc Frequently Asked Questions

What is ZyVersa Therapeutics Inc(ZVSA)'s stock price today?
The current price of ZVSA is $1.05. The 52 week high of ZVSA is $25.00 and 52 week low is $0.98.
When is next earnings date of ZyVersa Therapeutics Inc(ZVSA)?
The next earnings date of ZyVersa Therapeutics Inc(ZVSA) is .
Does ZyVersa Therapeutics Inc(ZVSA) pay dividends? If so, how much?
ZyVersa Therapeutics Inc(ZVSA) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1